For type 2 diabetes, the modern bar isnt just does it lower the number, its does it prevent heart attacks, strokes, and kidney decline. The injectable GLP-1s earned their place by proving that in dedicated outcomes trials, and this drug will have to as well. Further research, Carroll said, should also smartly test different starting doses and escalation speeds and how they impact potential side effects, and a rigorous head-to-head comparison against what oral GLP-1 options are already available
Schumacher, H
Performance will suffer, and the battery may fail prematurely
Retatrutide appears to cause more GI side effects than semaglutide, particularly nausea and vomiting, especially at higher doses
Genetic, dietary, and lifestyle differences between these populations could influence outcomes